Background {#s1}
==========

Rare and dangerous Erdheim-Chester disease (ECD) is a histiocytosis, histologically characterised by xanthomatous infiltrate by histiocytes that show CD68 but not CD1a markers.[@R1] It may affect any organ, but especially bones, heart, great vessels, neurohypophysis, orbits, eyes, cerebellum, retroperitoneal space and lungs.[@R2] It predominantly affects adult men.[@R1] William Chester and Jakob Erdheim published the first case in 1930 as a lipoid granulomatosis.[@R2] Seven hundred and fifty cases have been reported to date,[@R2] most of them in the last 15 years.[@R2] The first case in PubMed is dated 1978.[@R8] The first report about ophthalmological manifestations appeared in 1983.[@R9] Despite the fact that ECD has no cure[@R3] and that historically the prognosis has been bad, especially in patients with central nervous system involvement,[@R3] prognosis improved when interferon alpha was introduced into its treatment in 2001,[@R3] based on a previous experience in Langerhans cell histiocytosis (LCH).[@R14] More therapeutic and understanding progress has been made since 2012, when a case was reported of ECD that presented the V600E mutation of the BRAF gene,[@R15] which is involved in cell proliferation through the mitogen-activated protein kinase (MAPK) cell signalling system from cell surface to DNA in nucleus.[@R16] This mutation had previously shown to be present in more than 50% of LCH cases[@R17] and later in almost 50% of cases of ECD,[@R2] which has allowed ECD,[@R2] and also LCH,[@R27] to be treated with BRAF gene inhibitors. The discovery of other mutations in MAPK[@R2] and in other cell signalling systems,[@R20] and the fact that many patients who do not present V600E BRAF do present these other mutations,[@R2] confer more possibilities of treatment with gen inhibitors,[@R2] which has supposed better outcomes in survival analysis.[@R2] Real-time genomic profiling of histiocytes should allow these new treatments to be given without delay.[@R36] Despite these treatment advances, there is not yet a fully standardised treatment of ECD. A consensus guideline was published in 2014,[@R37] which has not been updated since. In general, interferon alpha is considered to be the first-line treatment. In the case of disease progression despite interferon therapy, a clinical trial with a BRAF inhibitor for BRAF-positive patients is indicated and, for those BRAF negative, either an antineoplastic (anakinra, imatinib, cladribine or cyclophosphamide)[@R3] or a clinical trial with the newer gene inhibitors is indicated. Bone marrow transplantation has been resorted to in some cases.[@R41]

ECD is clinically and biologically similar to LCH except that histiocytes in LCH are CD1a positive,[@R2] which is the reason why ECD has classically been defined as a non-Langerhans histiocytosis[@R3]; however, since 2016, it has been included in the Langerhans group of histiocytosis.[@R1] Other groups of histiocytosis are: cutaneous and mucocutaneous histiocytosis, Rosai-Dorfman disease, malignant histiocytosis and haemophagocytic lymphohistiocytosis and macrophage activation syndrome. By this classification, based on histological, molecular, clinical and image criteria, more than 100 subtypes of histiocytoses have been grouped in five groups.[@R1] There has been disquisition about if histiocytoses represent an inflammatory disorder or a neoplasia.[@R2] The oncogenic mutations found in a high percentages of LCH and ECD cases confer a clonal character to these diseases.[@R2] There is some ontogenic evidence that histiocytes of LCH and ECD might come from bone-marrow precursors.[@R2] In consequence, ECD and LCH are considered now by many as a myeloid neoplasia,[@R2]although inflammation is a prominent manifestation.[@R2]

The present case is relevant because it proves that tamponade, a severe ECD heart complication, may be overcome by pericardiectomy, a different method to that normally undertaken; it discloses that lacking appendicular bone involvement, a clinical aspect considered as universal in ECD,[@R3] does not rule it out; it exemplifies that interferon, the most recognised treatment for ECD, may be difficult to apply because of a challenging skin reaction that we describe; it points out a particularity in orbital imaging of ECD exophthalmos that helps in differential diagnosis; and it contributes to the knowledge of a rare and not yet fully characterised disease.

Case presentation {#s2}
=================

A 69-year-old Caucasian woman came to the internal medicine outpatient service referred for aetiological diagnosis of exophthalmos that had appeared 6 months earlier. She had been complaining of itching, eye dropping and conjunctival irritation. More recently, she had noticed eye protrusion ([figure 1A](#F1){ref-type="fig"}). She also complained of facial pain in maxillary region. She had been diagnosed as having diabetes insipidus 7 years earlier and has been treated with desmopressin since then.

![(A) Proptosis and red and redundant conjunctiva (conjunctivochalasis), before treatment with interferon and corticoids. Pupils are dilated with epinephrine for fundus examination. (B) Remission of proptosis, conjunctiva inflammation and conjunctivochalasis after treatment with interferon and corticoids.](bcr-2018-225224f01){#F1}

Orbital MRI showed intraconal fat tissue occupation and infiltration ([figures 2A, B, 3A, B and C](#F2 F3){ref-type="fig"}) that embraced the extrinsic ocular musculature ([figures 2 and 3](#F2 F3){ref-type="fig"}), which looked thinned and compressed ([figures 2A,B and 3C](#F2 F3){ref-type="fig"}) and caused retroocular compression and important bilateral exophthalmos ([figure 2C](#F2){ref-type="fig"}). There was also wall thickening of sphenoid and of both maxillary sinuses ([figures 2B and 3B,C](#F2 F3){ref-type="fig"}). The sella turcica was small, the posterior pituitary lobe was absent and the anterior one was normal ([figure 4](#F4){ref-type="fig"}).

![Severe bilateral proptosis due to retroocular compression because of intraconal fat infiltration that embraced extrinsic ocular musculature, which looks thinned and compressed, on orbital MRI with gadolinium (MRI), axial T1 view, before treatment with interferon and corticoids (A), plus sphenoid bone hypointensity suggesting osteosclerosis and mucous thickening within the sinuses on axial short-TI inversion recovery MRI (B), before interferon alpha treatment. Figure part C shows severe measured proptosis in axial T1 orbital axial MRI with gadolinium before treatment with interferon alpha.](bcr-2018-225224f02){#F2}

![Severe intraconal fat tissue infiltration on a coronal T1 orbital MRI (A), plus maxillary infiltration on coronal STIR MRI (B), before interferon alpha treatment. Extrinsic ocular musculature looks thinned embraced by severe intraconal fat tissue infiltration, and there is maxillary bone and mucous thickening on T1 coronal orbital MRI with gadolinium (C), before interferon alpha treatment.](bcr-2018-225224f03){#F3}

![Absence of the posterior pituitary T1 bright spot concordant with diabetes insipidus, normal anterior pituitary lobe, small sella turcica and wall thickening of sphenoid sinus in a sagittal T1 MRI.](bcr-2018-225224f04){#F4}

Ophthalmological examination ([figure 1A](#F1){ref-type="fig"}) showed proptosis, limitation of all eye movements, red conjunctiva, conjunctivochalasis (redundant conjunctiva), superficial punctate keratopathy in biomicroscopy on left eye, inferior eyelid retraction, normal visual acuity in right eye and nearly normal in the left eye, increased intraocular pressure in right eye and epiphora in left eye with nasolacrimal duct obstruction evidenced by probing. There was not diplopia or lagophthalmos.

A full anterior hypophyseal hormonal evaluation was normal.

Two months later, she presented dyspnoea, orthopnoea and dry cough, the latter especially in decubitus position. We noticed prominent jugular ingurgitation, arterial pulse decrease on inspiration and low cardiac tones. A Doppler echocardiogram confirmed cardiac tamponade. The patient clearly improved after pericardiocentesis. The exophthalmos improved after treatment with intravenous methylprednisolone pulses followed by oral prednisone.

However, both exophthalmos and tamponade came back soon, more severe and menacing. Transthoracic echocardiography showed a heterogeneous mass, 3 cm by 2.5 cm, next to the right coronary sulcus, which could compress the right ventricle ([figure 5](#F5){ref-type="fig"}) in addition to pericardial effusion. We decided that pericardiectomy should be performed to resolve tamponade. Cardiac surgeons found a yellow tissue mass that infiltrated cardiac fat. This lesion reminded them of ECD, based on previous experience.[@R3] Histological examination of pericardial tissue showed fibrotic chronic inflammatory infiltrate ([figure 6](#F6){ref-type="fig"}) composed of lymphocytes and cumulus of foamy CD68 positive/CD1a negative histiocytes ([figure 7](#F7){ref-type="fig"}). Based on this information and on clinical data, we considered that the patient suffered from ECD.[@R3] Deoxyribonucleic direct sequencing for BRAF gene, requested for therapeutic purposes, was negative.

![Heterogeneous mass, 3 cm by 2.5 cm, yellow arrow, next to the right coronary sulcus, which could compress the right ventricle, in transthoracic echocardiography.](bcr-2018-225224f05){#F5}

![The pericardial tissue histological examination shows fibrotic tissue and diffuse mononuclear infiltration of histiocytes and small lymphoid aggregates (A: H&E stain at 100×). The histiocytes show a large pale staining and foamy cytoplasm (B: H&E stain at 400×).](bcr-2018-225224f06){#F6}

![The immunohistochemical stain was positive for CD68 (A) and negative (no reaction) for CD1a (B).](bcr-2018-225224f07){#F7}

At that moment, our patient did not complain of appendicular bone pain, and we did not find suggestive osteosclerotic lesions on appendicular bones on either simple X-ray or Fludeoxyglucose (18F) Positron Emission Tomography-Computed Tomography (18F-FDG PET-CT), which did not include the arms and the legs beyond the distal portion of the femurs, or on technetium Tc 99 m hydroxydiphosphonate (99mTc-HDP) bone scan, the second performed later, once the patient was under treatment with corticoids and interferon alpha, all of them considered highly characteristic of ECD,[@R3] 99mTc-HDP more sensitive than 18F-FDG PET-CT for this purpose.[@R47] 18F-FDG PET-CT neither evidenced aortic inflammation, which is also frequent in ECD,[@R3] nor did the hairy kidney pattern, a frequent and very specific sign on abdominal CT.[@R48] However, 18F-FDG PET-CT did show diffuse increased metabolism of extrinsic ocular musculature, retroocular soft tissue increased density with normal metabolism ([figure 8](#F8){ref-type="fig"}) and pericardial effusion with normal metabolism.

![Diffuse increased metabolism of extrinsic ocular muscularity and retro-ocular soft tissue increased density with normal metabolism in 18F-FDG PET-CT before treatment with interferon alpha and corticoids.](bcr-2018-225224f08){#F8}

Differential diagnosis {#s3}
======================

Bilateral exophthalmos ([figure 1](#F1){ref-type="fig"}) and retro-orbital MRI ([figures 2 and 3](#F2 F3){ref-type="fig"}) made us think of several entities. ECD ophthalmopathy is similar to Graves' ophthalmopathy (GO)[@R51]; however, extrinsic ocular muscles look enlarged and orbital fat is not infiltrated in GO radiological imaging,[@R53] while the first looked thinned and compressed and the later infiltrated in our patient, in whom antithyrotropin antibodies were negative, while they are positive in 97% of patients suffering severe GO,[@R55] as well as thyroid function has remained normal in her, while there is hyperthyroidism in 90% of patients suffering GO.[@R53] Retro-orbital lymphoma[@R56] and granulomatosis with poliangiïtis (GPA)[@R59] may present as our patient did. As in our patient, paranasal sinuses are frequently involved in GPA radiological images, which also show bone erosion[@R62] that was not present in our case. Furthermore, antineutrophil cytoplasmic antibody were negative in our patient while they are positive in 4 of 5 patients with active GPA disease.[@R63] Anterior uveitis is the most common manifestation of orbital sarcoidosis (OS),[@R64] but OS may be present without uveitis, even without systemic disease,[@R65] so it could resemble our case; however, OS usually clinically manifests as a palpable mass or as eyelid swelling, different from our patient who presented diffuse severe exophthalmos, and radiologically lacrimal gland infiltration, optic nerve sheath, dural infiltrations are frequent OS manifestations,[@R65] which were not present in our patient. Idiopathic orbital inflammation would clinically and radiologically reassemble our case,[@R67] except for the fact that it is usually unilateral and acute,[@R67] that making a strong difference. Immunoglobulin G4-related ophthalmic disease could also resemble our case,[@R71] but it typically involves lacrimal gland,[@R71] trigeminal branch and extraocular muscles, which appear enlarged[@R72]; all of these were not present in our patient. Uncommon orbital metastases,[@R73] sometimes without primary malignancy,[@R73] sometimes bilateral[@R73] and sometimes manifested as enophthalmos,[@R70] except for the latter, could present in a similar way to our patient; however, MR or CT patterns of orbital metastases may have some specificity,[@R73] but not always. Tolosa-Hunt syndrome,[@R78] orbital rhabdomyosarcoma[@R79] and postseptal cellulitis,[@R81] because of unilaterality, rapid instauration or characteristic radiological images were not considered.

Orbital biopsy, usually a fine-needle aspiration biopsy, sometimes an open biopsy[@R58] or, more convenient, a sutureless aspiration cutter biopsy[@R84] is normally necessary to achieve a diagnosis in these settings.[@R56] The Ophthalmology service postponed performing a biopsy until having more results. Then the patient suffered the pericardial complications that conduced to the pericardiectomy that proportionated the tissue for histological diagnosis.

Treatment {#s4}
=========

Pericardiectomy definitively resolved the cardiac problems, but severe exophthalmos remained. As interferon is the most widely proposed first drug in ECD treatment and as it is associated with increased survival,[@R3] we prescribed pegylated interferon-alpha-2a, Pegasys, at 135 µg per week, by subcutaneous route, together with methylprednisolone pulses by intravenous route, 500 mg per week for 6 weeks, then 250 mg per week for a further 6 weeks, with a total of 4.5 g. We prescribed zoledronic acid in order to prevent osteoporosis induced by corticoids. The exophthalmos progressively improved to almost normalisation ([figure 1B](#F1){ref-type="fig"}). Facial bone pain disappeared, and wall thickening of sphenoid and maxillary sinuses improved.

Outcome and follow-up {#s5}
=====================

After receiving the ninth dose of interferon, the patient suffered from a generalised exanthema with itching and desquamative macular skin lesions on the arms, thorax, dorsa, abdomen and legs: everywhere except for the face ([figure 9](#F9){ref-type="fig"}). Examination of a punch cutaneous biopsy was indicative of a lichenoid drug eruption. Oral prednisone, topical triamcinolone and oral hydroxyzine provided some benefit. As we considered interferon therapy to be necessary, we kept prescribing it. The next three interferon administrations were somewhat better tolerated; however, after the fourth administration, the generalised exanthema became severely exacerbated and unbearable. At that time, the exophthalmos had remitted. Considering both the adverse skin reaction and the exophthalmos remission, we stopped interferon. The patient had received 15 doses in total. The generalised desquamative exanthema improved to complete remission in 4 weeks. Diabetes insipidus did not show any modification, either improvement or worsening, throughout the process with us. The exophthalmos has kept in remission despite interferon alpha suppression and despite no more corticoid administration.

![Generalised erythematous scaly plaques on the trunk, abdomen and extremities, which appeared during pegylated interferon-alpha-2a.](bcr-2018-225224f09){#F9}

Discussion {#s6}
==========

It was a challenging process to obtain the diagnosis in our patient, because it was elusive, the disease was rare and severe and because it encompassed a considerable delay. Such difficulties are not unusual in ECD. Initially, when our patient presented exophthalmos and long-lasting diabetes insipidus but not yet heart disease, we did not suspect ECD, despite the fact that the association of exophthalmos and diabetes insipidus poses a strong suspicion of such disease.[@R3] It was not until she presented heart tamponade that we considered a histiocytosis as a possible cause. However, the fact that we did not find appendicular bone involvement, reported as nearly always being present in histiocytosis, including ECD,[@R5] made us think of histiocytosis as a remote aetiology. Despite the fact that some cases of delayed[@R104] or lacking[@R105] bone involvement have been described, absence of bone involvement has meant that ECD was only diagnosed postmortem in some patients.[@R106] Consequently, ECD should not be ruled out because of the absence of appendicular bone involvement. Our patient had painful facial bone involvement ([figures 2B and 3B,C](#F2 F3){ref-type="fig"}), which is frequent in ECD.[@R107] What is infrequent is to find axial bone involvement without appendicular bone involvement,[@R107] as in our case. Perhaps if we had requested 99mTc-HDP bone scan previously to the interferon and corticoid treatment or if 18F-FDG PET-CT had included the whole extremities, we would have detected it. We prescribed zoledronic acid to prevent steroid-induced osteoporosis and interferon to treat exophthalmos. Zoledronic acid, alone[@R117] or combined with interferon alpha,[@R98] has been reported to be very useful to treat axial ECD bone involvement, as it was in our patient.

Diabetes insipidus is a frequent manifestation of ECD[@R119] that either precedes[@R89] or sometimes coincides[@R131] with other manifestations of the disease but rarely follows them.[@R135] This sequence of events frequently causes a delay in establishing ECD as the cause of diabetes insipidus,[@R5] as occurred in our case. However, diabetes insipidus onset in an adult should arouse suspicion of an extracranial disease involving the pituitary stalk. Among them histiocytoses are prominent and can be detected early by means of 18F-FDG PET-CT[@R122] or brain MRI with gadolinium.[@R87] This is important because ECD-associated diabetes insipidus only responds to ECD therapy when administered soon after diabetes insipidus onset[@R98]; if treatment for ECD is delayed, which frequently occurres,[@R139] as in our case, it does not resolve diabetes insipidus. Our patient did not present any anterior hypophyseal hormonal disorder, which has been reported as very frequent in ECD when looked for.[@R119]

Patient's exophthalmos characteristics were in concordance with what is described in ECD.[@R51] Fortunately, she did not suffer blindness, which is frequently reported in ECD.[@R51] Orbital MRI of the patient ([figures 2 and 3](#F2 F3){ref-type="fig"}) were also in line with what is commonly reported,[@R51] including thinned and compressed extrinsic ocular musculature ([figures 2A and 3C](#F2 F3){ref-type="fig"}).[@R52] The latter may be useful to distinguish between exophthalmos caused by ECD and that caused by Graves' disease, in which extrinsic ocular muscles appear enlarged in a spindle shape.[@R142] Exophthalmos did not persistently remit until we added interferon alpha to corticosteroids, in accordance with other experiences[@R51] and has remained in remission after stopping them. The patient did not need orbital decompression, often required in ECD.[@R143] Also, she did not present eyelid xanthelasma ([figure 1A,B](#F1){ref-type="fig"}), which is frequently associated with exophthalmos in ECD.[@R9]

The heterogeneous mass seen on the echocardiogram in our patient ([figure 5](#F5){ref-type="fig"}) has been described in other cases.[@R5] In our case, the cardiologist determined that this mass compressed the right ventricle so that it could contribute to the heart tamponade. It has been reported that masses like this cross the atrial wall.[@R148] Mortality related to cardiovascular involvement in ECD is high.[@R147] Our patient survived a menacing recurrent tamponade that definitively remitted with pericardiectomy. Many authors have reported tamponade in ECD.[@R93] Some consider tamponade as a dangerous rarity within heart involvement in ECD.[@R93] In a case similar to ours, the authors obtained an excellent result with pericardiectomy for severe tamponade.[@R155] We agree with them that pericardiectomy has to be considered as a reasonable therapeutic option for menacing recurrent tamponade in ECD.

Should ECD manifestations reappear, we would not give her pegylated interferon because of the bothersome skin reaction she suffered, which has been described in patients receiving pegylated interferon-alpha-2a and interferon-alpha-2b for hepatitis C or B.[@R159] Since deoxyribonucleic direct sequencing for BRAF was negative, theoretically, there is no option to treat her with the BRAF inhibitors.[@R43] We have requested mitogen-activated protein kinase 1 (MAP2K1) and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations detection because there is evidence of successful results treating patients with refractory histiocytosis with MAP2K1 and PIK3CA inhibitors.[@R36]

###### Patient's perspective

This morning the doctor asked me to write a summary of the process of my disease, basically how I have felt physically and mentally. I feel unhappy to have to recall everything about my disease, but I want to express my gratitude to the doctors who have taken care of me, because of their medical and psychological help. I want to contribute as much as I can to research into my disease.

We are in the summer of 2015, in the house by the beach and I feel quite well. I have had to overcome the death of my granddaughter.

Near the end of the summer I began to notice discomfort in my eye, so I went to my ophthalmologist, and she prescribed eye drops for me and told me to come back in a few days. This was repeated for three times, my discomfort became worse, so the ophthalmologist ordered a cranial magnetic resonance to be performed on me. When I heard the radiologist comment that he was surprised that this test was requested by an ophthalmologist, I became very worried.

With the results, at the beginning of January 2016, that said that I had bilateral exophthalmos, more on the left side than on the right, I went back to the ophthalmologist who, when she saw the results, called another doctor to have her opinion about this result. They told us that there was a tumour behind my eye and that the best we could do was to go to a public hospital, since this could have a complicated and prolonged treatment. I do not think that either the formalities or the manners to deal with this issue were the most appropriate, and because all of this, I felt completely abated, without hope of any improvement or solution.

At this moment I remembered a friend of mine, far younger than me, who had been diagnosed with the same brain tumour behind an eye and who had left us after having suffered a real ordeal.

My perspective was very bad, I needed medical and psychological help, and also guidance about the path to follow, and all of this urgently. I decided to visit two doctors, one of them, a friend of mine who, after I had explained my situation to him, told me that he would give me only one piece of advice: 'in a referral hospital you will be in the hands of the best specialists, do everything they tell you to do, do not ask for second opinions and do not think of changing to another hospital', the second doctor, with whom we have a good relationship, she is our neighbour, and she was a consultant in a referral hospital. She gave me a lot of moral support. She helped to get me seen in a referral hospital, which I did not know how to do, and she has always stood by me, giving me advice and offering me the best support at all times.

In January 2016, I entered the outpatient services of the definitive tertiary referral hospital, being in very bad condition.

I was attended by a doctor who carried out a complete examination and who also reviewed all the documentation that I brought. I felt insecure, worried and afraid, I did not know what the future would hold for me, but I thought that it would not be long and nothing good. I think that the doctor was fully aware of the situation. The interest and the sensitivity of the doctor alleviated me a little.

Different specialists performed many tests on me in order to know the exact disease that I had, which was complex and generated doubts among the different specialists. This uncertainty brought me a lot of anxiety.

In one of the many visits to the doctor he decided to admit me immediately to the coronary unit to remove liquid from the pericardium. To tell the truth I felt very frightened and I came to think that I would not survive.

Some time later it seems that the liquid in the pericardium came back so the medical team decided that I should be immediately admitted to hospital in order to be operated on to remove my pericardium. After the operation I felt more at ease, the operation had gone well and the doctors told me that like this the liquid would not come back any more.

Some adherences of uncertain appearance were found, so they were taken to be examined in pathology, which determined, without any doubt, that I had Erdheim-Chester disease. Alleviated because I knew what I had but doubtful because it is a rare disease, the doctor reassured me because he said that we would carry out a treatment to fight and overcome it.

The postoperative period went quite well; I felt that my family helped a lot, as well as my doctor and all who attended to me. I started to have hope.

When discharged from hospital, the medication started:

1.  Methylprednisolone 500 mg per week for 6 weeks and 250 mg per week for a further 6 weeks.

2.  Pegasys 135, every Friday, five boxes (four prefilled pen per box).

Two months later I felt quite better.

After having received five boxes of interferon, it had to be suspended because, despite the fact that the exophthalmia improved, it attacked my skin and produced plenty of big spots on the whole of my body, except for my face. I felt very bad.

I started 2017 with my dermatitis and my exophthalmos improving slowly and progressively, without completely disappearing.

However, the disease attacked me again (1), it caused severe diarrhoea that prevented me from leaving home. At the beginning I stayed on a diet for many days but I did not get better. I felt bad, insecure and miserable.

In May, they performed a colonoscopy on me, and they immediately prescribed budesonide for 8 weeks and cholestyramine. The chronic diarrhoea improved, and in 2 months I feel much better and I started to feel confident again.

In one of the many visits to the doctor, he found me very unhappy; I told him that I was sleeping badly, and he prescribed Cymbalta; some days later I quickly improved, I felt lively and happy.

They have told me that the disease has attacked my shoulder; I cannot raise my arms above my shoulders. (2) I have to be accompanied in the street because sometimes I have fallen. I have much physical pain (3) but I am happy and hopeful, I have everything: my family, the best doctor and my hospital, so I try not to be far away, I have complete confidence and I have the strength to keep going.

Josefina Casas Pascual

20 February 2018.

###### Learning points

-   Do not clinically discard Erdheim-Chester disease because of non-existent appendicular bone pain or appendicular bone image involvement; they may be last to appear.

-   Diabetes insipidus onset in an adult should arouse suspicion of extracranial disease involving the pituitary stalk, of which histiocytoses are prominent.

-   Extrinsic ocular musculature on orbital magnetic resonance looks thinned and compressed in Erdheim-Chester disease while it appears enlarged in Graves' disease.
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